ANVISA’s strange examples [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2022-03-21 18:38 (56 d 01:29 ago) – Posting: # 22857
Views: 450


THX for providing the data! If others are interested you may download them (in CSV-format).

» I have done the pharmacokinetic analysis using Phoenix WinNonlin 8.3…
» Could anybody help me how to calculate/formula/logic of Kel Value calculations as per ANVISA Regulatory?

No logic, only bad practices.

First of all, from subjects where concentrations are relatively high it is clear that the drug follows a two-com­part­ment model. In subjects with low concentrations only the distribution phase is visible, explaining also the reported half lives ranging from 0.57 to 9.55 hours.
The default automatic algorithm in Phoe­nix WinNonlin (and most other software I know) is starting with the last three concentrations and maximizing \(\small{R_\textrm{adj}^2}\) until the improvement by adding data is ≤0.0001. So far, so good.
It was kind of a scavenger hunt to unveil what the ANVISA did. By trial-and-error I was successful at the end. Don’t know which software was used but for many years tmax|Cmax is not included by the algo because absorption is not complete. Another example:
Since the automatic algo might fail (sometimes with two-compartment models, regularly with drugs showing enterohepatic recycling, controlled release products with flat profiles, multiphasic release products), visual inspection of the fits is mandatory.

   The selection of the most suitable time interval cannot be left to a programmed algorithm based on mathematical criteria, but necessitates scientific judgment by both the clinical pharmacokineticist and the person who determined the concentrations and knows about their reliability.1
   It should be emphasised that the TTT method has been introduced in this paper to provide a reasonable tool to support visual curve inspection for reliably identifying the mono-exponential terminal phase. Moreover, the TTT method should not be utilised without visual inspection of the respective concentra­tion-time course. Thus, before using this new approach the monophasic shape post the peak of the curve has to be checked visually by means of a semilogarithmic diagram.2

But what do we see in ANVISA’s examples? In many cases tmax|Cmax was included. Outdated software?3 In some cases a quite reasonable automatic fit was changed to the worse. Very bad: The fits were corrected about three times as often for R than for T. If we would do that, an assessor might suspect cherry-picking (intentionally changing the T/R-ratio of AUC0–∞).

My procedure (of course, outlined in the protocol):

  1. Hauschke D, Steinijans VW, Pigeot I. Bioequivalence Studies in Drug Development: Methods and Appli­cations. New York: Wiley; 2007. p. 20-3.
  2. Scheerans C, Derendorf H, Kloft C. Proposal for a Standardised Identification of the Mono-Exponential Terminal Phase for Orally Administered Drugs. Biopharm Drug Dispos. 2008; 29(3): 145–57. doi:10.1002/bdd.596.
  3. Including tmax|Cmax was implemented in ‘classical’ WinNonlin till v5.3 of 2009. The ANVISA’s manual is of 2002. Maybe that’s the reason.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,074 posts in 4,629 threads, 1,565 registered users;
online 8 (0 registered, 8 guests [including 7 identified bots]).
Forum time: Monday 21:07 CEST (Europe/Vienna)

Rules are for the guidance of wise men
and the blind obedience of fools.    attributed to Solon

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz